New approaches might lower drug prices

09/26/2013 | Reuters

Targeted clinical trials, wherein compounds are tested on patients with specific genetic traits, might lower development costs and subsequent prices for promising immunotherapies. Drugmakers are also experimenting with combinations of existing treatments that might cost less than single compounds. The FDA has become more flexible, speeding the approval process for drugs designated as breakthroughs and giving others priority review.

View Full Article in:

Reuters

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Paralegal
Mylan Inc.
Washington, DC
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director of Actuarial Services, Government Programs
PacificSource
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC